Identification of Novel Skeletal Muscle-derived Factors That Promote Lipid Oxidation in Both Skeletal Muscle and Adipose Tissue
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Obesity
- Sponsor
- AdventHealth Translational Research Institute
- Enrollment
- 56
- Locations
- 1
- Primary Endpoint
- Measure change in mitochondrial capacity
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
The purpose of this study is to collect data to help researchers identify factors, such as certain proteins or genetic codes, that are secreted from muscle that are associated with the beneficial effects of exercise.
Detailed Description
Study Objectives: 1. To identify specific changes in messenger ribonucleic acid (mRNA)/micro ribonucleic acid (miRNA) expression in muscle associated with higher or lower relative measures of mitochondrial capacity and fat oxidation. 2. To identify secreted factors/miRNAs that specifically relate to the metabolic response of muscle and that are present after a single initial bout of exercise. 3. To collect the appropriate clinical samples (muscle and adipose tissue, plasma/serum) to enable validation of myokines associated with changes in oxygen consumption/mitochondrial content via in vivo and in vitro discovery efforts.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Applicable to all Groups
- •Healthy men and women, aged 18 - 40, inclusive.
- •Willing to stop alcohol and caffeine consumption for 48 hours preceding each blood draw
- •Applicable to Group 1
- •BMI between 22 and 29.9 kg/m2
- •Not involved in regular exercise program
- •Willing to exercise every day for the study period
- •Applicable to Group 2
- •BMI between 22 and 29.9 kg/m2
- •Maximal oxygen uptake (VO2max) ≥ 45 ml/kg fat-free mass
Exclusion Criteria
- •Applicable to All Groups
- •History of Type 2 Diabetes
- •"Unfavorable anatomy" for continuous venous blood sample collection
- •Abnormal resting ECG
- •Significant renal, cardiac, liver, lung, or neurological disease (controlled hypertension is acceptable if baseline bp \< 140/90 on medications)
- •Use of drugs known to affect energy metabolism or body weight: including, but not limited to: orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc
- •Current treatment with blood thinners or anti-platelet medications that cannot be safely stopped for testing procedures
- •New onset (\<3 months on a stable regime) use of oral contraceptives or hormone replacement therapy
- •Alcohol or other drug abuse
- •Smoking within the past 3 months
Outcomes
Primary Outcomes
Measure change in mitochondrial capacity
Time Frame: Baseline (Day -6), Day 18
The difference will be measured in obese, lean and athletic participants. The Phosphocreatine (PCr) recovery time constant and the PCr level in oxygenated muscle at rest will be used to calculate maximum mitochondrial capacity.
Secondary Outcomes
- Measure change of expression of proteins(Baseline (Day -6), Day 0, Day 5, Day 12, Day 18)
- Measure change in mRNA/miRNA levels(Baseline (Day -6), Day 0, Day 5, Day 12, Day 18)